Register entry
- Registered sites
- 3
- Active NDC listings
- 13
- Live patents
- 0
- Countries
- 1
- Base
- Japan
Authorisation
Registered operations
Analytical testing3Active ingredient (API) manufacture2Finished drug manufacture3
Sites
Registered establishments
3| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Chugai Pharma Manufacturing Co., LtdRegistrant: Chugai Pharmaceutical Co., Ltd. | 2500 Takayanagi, Fujieda, SZO 426-0041, Japan (JPN) | Analytical testing, Finished drug manufacture | 3002806758716464883 |
| Chugai Pharma Manufacturing Co., LtdRegistrant: Chugai Pharmaceutical Co., Ltd. | 5-5-1, UKIMA, Kita-ku, TKY 115-0051, Japan (JPN) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3004109596691033815 |
| Chugai Pharma Manufacturing Co., LtdRegistrant: Chugai Pharmaceutical Co., Ltd. | 16-3 Kiyohara Kogyodanchi, Utsunomiya, TCG 321-3231, Japan (JPN) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3006942691716464891 |
Catalogue
Drug listings by form and route
1313 active NDC listings: 13 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 13.
| Dosage form | NDCs |
|---|---|
| injection, solution | 6 |
| injection, solution, concentrate | 3 |
| liquid | 3 |
| capsule | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| chugai pharmaceutical co., ltd. | 13 |
Catalogue
Marketed products
13| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | Alectinib Hydrochloride | capsule | 60422-211DRUG FOR FURTHER PROCESSING |
| - | Emicizumab | injection, solution | 60422-260DRUG FOR FURTHER PROCESSING |
| - | Emicizumab | injection, solution | 60422-270DRUG FOR FURTHER PROCESSING |
| - | Emicizumab | injection, solution | 60422-280DRUG FOR FURTHER PROCESSING |
| - | Emicizumab | injection, solution | 60422-290DRUG FOR FURTHER PROCESSING |
| - | Emicizumab | liquid | 60422-302DRUG FOR FURTHER PROCESSING |
| - | Nemolizumab | liquid | 60422-402DRUG FOR FURTHER PROCESSING |
| - | Satralizumab | injection, solution | 60422-367DRUG FOR FURTHER PROCESSING |
| - | Tocilizumab | liquid | 60422-202DRUG FOR FURTHER PROCESSING |
| - | Tocilizumab | injection, solution | 60422-220DRUG FOR FURTHER PROCESSING |
| - | Tocilizumab | injection, solution, concentrate | 60422-230DRUG FOR FURTHER PROCESSING |
| - | Tocilizumab | injection, solution, concentrate | 60422-240DRUG FOR FURTHER PROCESSING |
| - | Tocilizumab | injection, solution, concentrate | 60422-250DRUG FOR FURTHER PROCESSING |
Neighbours
Registered in the same town
1- Hisamitsu Pharmaceutical Co., Inc.Utsunomiya, JPN
Compare
Comparable companies in Japan
- Daiichi Sankyo Europe GmbH3 sites · 11 NDC
- Sumitomo Chemical Company, Limited3 sites · 8 NDC
- Meiji Seika Pharma Co., Ltd.3 sites · 1 NDC
- Sumitomo Pharma Co., Ltd.2 sites · 24 NDC
- TAYCA CORPORATION2 sites · 22 NDC
- Shionogi Pharma Co., Ltd.4 sites · 17 NDC
- Hisamitsu Pharmaceutical Co., Inc.2 sites · 16 NDC
- Terumo Pharmaceutical Services GmbH4 sites · 12 NDC
- Bushu Pharmaceuticals, Ltd.2 sites · 11 NDC
- ASO Pharmaceutical Co. Ltd.2 sites · 10 NDC
Enquiry
Common questions
- Is Chugai Pharmaceutical Co., Ltd. FDA approved?
- Chugai Pharmaceutical Co., Ltd. holds 3 FDA-registered establishments in Japan. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Chugai Pharmaceutical Co., Ltd.'s drugs manufactured?
- The FDA register lists Fujieda; Kita-ku; Utsunomiya. Registered operations: analytical testing, active ingredient (API) manufacture, finished drug manufacture.
- What drugs does Chugai Pharmaceutical Co., Ltd. make?
- 13 products are listed under Chugai Pharmaceutical Co., Ltd. in the openFDA NDC Directory, most often as injection, solution; injection, solution, concentrate; liquid. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.